Americans elect their leaders on the premise that those individuals will be capable of making the right decisions on difficult, as well as easy, issues. An issue on which members of Congress might ...
Eli Lilly’s obesity drug Zepbound is now covered by Medicare for sleep apnea treatment, expanding access to the costly ...
Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...
FOIA requests to the federal government often are signals. They can be an important early warning of bad publicity, litigation to come, or uncertainties to be hedged and gamed out. When the flow of ...
El Lilly’s (LLY) blockbuster weight-loss drug Zepbound is now eligible for Medicare coverage. The news could significantly ...
"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...
Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...
Recent market research reveals that glucagon-like peptide-1 (GLP-1) injections are set to dominate the obesity treatment ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
Eli Lilly's Tirzepatide Outshines Novo Nordisk's Semaglutide, Yet Brand Recognition Remains Strong for Novo's Products ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback